Khan Lab research

Research Focus

Investigating Molecular Mechanisms that Control Systemic Autoimmunity and SLE Pathogenesis 

Systemic Lupus Erythematosus (SLE) is a chronic multisystem autoimmune disease mediated by a complex interaction of genetic and environmental factors. The Khan Lab is investigating the role of novel lupus susceptibility genes in mediating lupus pathogenesis and defining the mechanisms and pathways that mediate systemic autoimmunity and the development of fatal lupus by utilizing congenic lupus mouse models, genomics, and high-dimensional approaches.

Mechanisms underlying Immune-related Adverse Events and Response Associated with Immune Checkpoint Inhibitor Therapy

Although immune checkpoint inhibitor (ICI) therapies have emerged as a remarkable treatment option for diverse cancer types, they result in unpredictable and often life-threatening immune-related adverse events (irAEs). Understanding of these autoimmune events remains poor and ill-defined. The Khan Lab is investigating the factors mediating the development of irAEs and defining the mechanisms underlying the autoimmune events in response to immunotherapy. We are also establishing novel preclinical mouse models to study irAE biology and response to ICI therapy. This work is supported by the MRA-SITC Young Investigator Award from the Melanoma Research Alliance and Society for Immunotherapy of Cancer.

Immune Landscape and Biology of High-risk Pediatric Solid Tumors

The Khan Lab is currently developing research to understand disease resistance in high-risk pediatric solid tumors. Immunotherapy has not yet shown much success in treating pediatric solid tumors—many patients who survive experience a wide array of treatment-related comorbidities. We are utilizing an integrated approach and novel technologies, including in vitro/in vivo models, to understand the immune composition and cellular interactions underlying disease resistance and recurrence to identify novel therapeutic targets for this fatal disease.